Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta, cisplatin, and radiotherapy in limited stage SCLC
NCT00447421Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2007
- Primary completion
- May 2008
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate. Started Feb 2007; status: terminated.
02
Drugs
pemetrexed
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00447421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447421.